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ABSTRACT 
 
Aim. Breast density is a risk factor for breast cancer. As density changes across a woman’s life 
span, we studied for how long a single density measurement taken in (post-)menopausal women 
remains informative.  
 
Methods. We used data from Singaporean women who underwent a single mammography screen at 
age 50-64 years. For each case with breast cancer diagnosed at screening or in the subsequent 10 
years, whether screen detected or diagnosed following symptoms, two age-matched controls were 
selected. We studied the excess risk of breast cancer, calculated as an odds ratio (OR) with 
conditional logistic regression and adjusted for body mass index, associated with 26-50% and with 
51-100% density compared to ≤25% density by time since screening.  
 
Results. In total, 490 women had breast cancer, of which 361 were diagnosed because of symptoms 
after screening. Women with 51-100% breast density had an excess risk of breast cancer that did 
not seem to attenuate with time. In 1-3 years after screening, the OR was 2.22 (95% CI: 1.07-4.61); 
in 4-6 years after screening, the OR was 4.09 (95% CI: 2.21-7.58), and in 7-10 years after screening 
the OR was 5.35 (95% CI: 2.57-11.15). Excess risk with a stable OR of about 2 was also observed 
for women with 26-50% breast density. These patterns were robust when the analyses were limited 
to post-menopausal women, non-users of hormonal replacement therapy, and after stratification by 
age at density measurement. 
 
Conclusion. A single breast density measurement identifies women with an excess risk of breast 
cancer during at least the subsequent 10 years. 
 
HIGHLIGHTS (max 85 characters, including spaces, per bullet point) 
 
- Dense mammographic areas confer an excess breast cancer risk for at least 10 years 
- This risk does not wane with time 
- The risk is not limited to women who took hormonal replacement therapy 
 
KEYWORDS 
 
Breast cancer, breast density, excess risk, screening, mammography  
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INTRODUCTION 
 
About 40% of women have heterogeneously or extremely dense breasts (as defined by Breast 
Imaging-Reporting and Data System, BI-RADS, categories 3-4; this typically involves dense tissue 
in ≥50% of the breast), of which ca. 5-10% have extremely dense breasts (BI-RADS 4; typically 
≥75% dense tissue).[1,2] In an extensive meta-analysis, adjusted for age, the relative risk (RR) of 
breast cancer in women with 50-74% dense breast tissue approached 3 (RR: 2.92, 95% CI: 2.49-
3.42) compared to women whose breasts are composed of >95% fatty tissue, while the relative risk 
in women with ≥75% dense tissue was estimated to be about 4-5 (RR: 4.64, 95% CI: 3.64-5.91).[3]  
 
Dense breast tissue is mainly fibroglandular and appears white instead of translucent on a 
mammogram and this whiteness can mask prevalent cancers.[4] At least 29% (95% CI: 27-31) of 
cancers in dense breasts are not detectable by mammography.[5] In a US study, taking into account 
symptomatic cancers diagnosed two years after a negative screening mammogram, the 
mammographic sensitivity was 72% overall, but only 30% in women with extremely dense and 
60% in women with heterogeneously dense breasts, whereas it was 80% in women with 
predominantly fatty breasts.[6] 
 
Breast density changes across a woman’s life course.[7,8] Most prominently, it decreases with age 
and, independently, with menopausal transition, as fibroglandular tissue is replaced with fat.[9,10] 
While density is associated with several non-modifiable factors such as genetics and race,[11,12] 
various modifiable factors also play a role such as women’s lifestyles[7,11,13-17] and use of 
medication such as hormonal replacement therapy (HRT), which increases density, or tamoxifen, 
which reduces it.[7,17-22]  
 
Given this dynamic in breast density, we investigated for how long a single density measurement 
taken at ≥50 years of age remains predictive of the excess risk of breast cancer.  
 
MATERIAL AND METHODS 
 
Study population 
 
The study population was described in detail previously.[23-28] Briefly, all women permanently 
residing in Singapore in 1994 aged 50-64 years (N=166,600) were randomised to either a single 
round of breast screening with mammography (N=69,473) or standard care; exclusion criteria were 
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a recent mammogram or breast biopsy, pregnancy, or history of cancer other than non-melanoma 
cancer. One thousand women invited to participate in the trial were aged 45-49 and 65-69 years. 
Between October 1994 and February 1997, 42% of the invited women underwent a two-view, film-
screen, mammographic examination that was evaluated by two radiologists. Women were managed 
according to the most suspicious of the two readings, and could be either discharged, recalled for 
further films, or recalled for joint assessment. Women’s socio-demographic characteristics were 
determined through a questionnaire administered at screening. Mammography screening was 
infrequent before the trial; after it had closed, mammography was only offered within a screening 
programme from 2002 onward but the coverage rate was below 40%.[29] The trial was approved by 
the National University of Singapore Institutional Review Board.  
 
Information on all breast cancers (including invasive and ductal carcinoma in situ cases, and both 
screen-detected cases as well as those diagnosed following symptoms) was retrieved until 2005 
from pathology records of the two participating screening hospitals or through linkage with the 
national cancer registry. Each screened woman with a breast cancer diagnosis (N=491) was 
matched on age and ethnicity with two women (N=982) with a mammogram who had not 
developed breast cancer; the same selection of cases and controls was studied previously by Wong 
et al.[25]  
 
Breast density measurements 
 
Density was estimated retrospectively using screening mammograms from both the cases and their 
matched controls. Although this work was undertaken after the case-control status had become 
known, the final disease status was not revealed during the density scoring process. Percent breast 
density was estimated in the contralateral breast using the quantitative Cumulus interactive 
threshold method.[30] This information was not used for clinical management. 
 
Statistical analysis 
 
The differences in the distributions of dichotomised sociodemographic risk factors (at most primary 
level of education, age at menarche ≤14 years, premenopausal status, no live births, and ever using 
HRT) between cases and their matched controls were assessed with conditional logistic regression. 
For the continuous measures of BMI and percent density, the differences (calculated as: [BMI 
control1 + BMI control2 - 2×BMI case]/2, and equivalent for percent density) were assessed using 
the t test. A Shapiro-Wilk test for non-normality was not significant: P=0.42 for BMI, and P=0.77 
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for percent density. The differences between cases and controls in the categorical distributions of 
breast density (classified as 0-10%, 11-25%, 26-50%, 51-75%, and 76-100%) were evaluated using 
the χ2 statistic. 
 
The risk of breast cancer associated with breast density was calculated with conditional logistic 
regression. When the risk was calculated by year since screening, percent density was categorised 
as ≤25%, 26-50%, and ≥51% to avoid cells with small numbers. To keep the models simple, they 
were adjusted for BMI only, while age and ethnicity were controlled for in the matching. In an 
earlier analysis of the same dataset,[25] further adjustment for age at menarche, number of 
deliveries, age at first birth, use of oral contraceptives, HRT use, and menopausal status did not 
substantially change the BMI-adjusted overall odds ratios (OR) for the association of density with 
breast cancer risk.  
 
All analyses were undertaken with R Studio version 1.1.419.  
 
RESULTS 
 
Of the 491 cancers, 129 (26%) were detected at screening within the trial and 362 (74%) were 
diagnosed outside of the trial, most likely as a result of seeking medical advice for symptoms. 
Among the 491 cases, 3 (1%) were younger than 50 years at screening, 157 (32%) were aged 50-54, 
196 (40%) 55-59, 115 (23%) 60-64, and 20 (4%) were aged ≥65 years. Cases were statistically 
significantly less likely to have at most primary education than controls; they were also more likely 
to have a higher BMI, be younger at menarche, to have ever used HRT, and were slightly more 
likely to be nulliparous and premenopausal (Table 1). These relationships were roughly preserved 
after stratification by mode of detection, although the numbers were smaller for women with 
screen-detected cancers and the differences did not reach statistical significance.  
 
Cases had significantly denser breasts than controls, with 22% of cases and 41% of controls having 
0-25% density and 34% of cases and 19% of controls having 51-100% density (Table 2). Cases had 
on average 42% of the mammogram area composed of dense tissue, whereas in controls this was 
33% (P<0.01). Breast density was correlated with age. Cases aged 50-54 years had a median 
percent density of 48, those aged 55-59 years 40, and those aged 60-64 35. Among controls, this 
was 38, 31, and 23, respectively (data not tabulated). 
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As expected, the risk of cancer detected at screening or in the subsequent 10 years increased with 
percentage of breast density, with about a five-fold increase in the risk in women with ≥51% 
density compared to women with ≤10% density (Table 3; OR for 51-75% density: 4.66, 95% CI: 
2.83-7.65, and OR for 76-100% density: 5.74, 95% CI: 2.54-12.95). Each percentage point increase 
in breast density was estimated to increase the risk of cancer by 3% (95% CI: 2-4). While the risk 
was substantially more pronounced for screen-detected cancers, it remained statistically 
significantly increased for symptomatic cancers.  
 
Only 19 (5%) of the 361 symptomatic cancers in our study were diagnosed within the first year 
after screening and the effect of breast density was not statistically significant (Table 4). Four to six 
years after screening when 150 (42%) symptomatic breast cancers were diagnosed, women with 26-
50% density had an OR of breast cancer of 2.17 (95% CI: 1.27-3.71) compared to those with ≤25% 
density, and those with 51-100% had an OR of 4.09 (95% CI: 2.21-7.58). One hundred and sixteen 
(32%) symptomatic cancers were diagnosed seven or more years after screening, when women with 
26-50% density still had an increased risk of breast cancer with an OR of 2.46 (95% CI: 1.32-4.58), 
as did women with ≥51% density, OR 5.35 (95% CI: 2.57-11.15). A test for interaction between 
breast density and time since screening was not significant, and consequently an interaction term 
was not included in the models. 
 
The same patterns were observed when the analysis was restricted to 270 (75%) out of 362 
symptomatic cancer case-control trios in which all three women were post-menopausal; when 
restricted to 227 (63%) of trios in which none of the women previously took HRT; when the 
analysis included only 310 (86%) trios that comprised of women of Chinese origin; and when 
stratified by age group (<56 years vs. ≥56, the sample’s median; data not reported).  
 
DISCUSSION 
 
A single mammographic measurement showing high breast density around or after menopause has 
long-term informational value for a woman’s excess risk of developing breast cancer. In our 
predominantly postmenopausal sample of women undergoing a single mammography screen at age 
50-64 years, the overall relative risk was about four in those with dense tissue covering at least half 
of their mammogram area compared to those with dense tissue in less than a quarter of their 
mammogram. This relationship was robust when analyses were stratified by age, postmenopausal 
status and use of HRT. This risk remained significantly elevated for at least 10 years and did not 
show a tendency to decline towards the end of the observation period.  
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To detect cancers in women with dense breasts missed by mammography, some countries are now 
offering complementary ultrasound screening.[31] Our results suggest that women with high breast 
density at age ≥50 years could be scheduled to undergo supplementary ultrasound screening, and 
remain being considered for the dual screening modality for the following 10 years. Nevertheless, 
additional studies would need to confirm whether this approach could be cost-effective and feasible 
given the available health care capacities. 
 
Our study was undertaken in a population of Asian descent with a somewhat higher average percent 
breast density than in many Western populations, although the proportion of women with ≥50% 
density was not exceptionally high.[7,10,32] Women in the trial underwent a single mammographic 
screen, although we could not ascertain whether any of them obtained additional mammography 
elsewhere, e.g. through the national screening programme rolled out in 2002. The Singapore cancer 
registry is highly complete[33] and emigration from the country was not high at least during the 
1990’s,[34] leading to limited, if any, misclassification of case-control status in our study.  
 
The observation that the ORs were substantially higher for screen detected cancers than for 
symptomatic cancers may be somewhat surprising. These ORs are driven not by very high rates of 
cancer detection in dense breasts but very low rates in non-dense breasts (Table 2). They are partly 
dependent on the baseline category. In our analysis this was very non-dense (≤10%), a relatively 
rare group in this population, which we suspect is confounded with a number of important but 
unobserved risk factors. If we had chosen ≤25% density as our baseline category, the ORs would 
have been of the order of 1.5-2 times higher for screen-detected, rather than 10 times higher as in 
Table 3. The results remain surprising, although not completely unprecedented. For example, 
Nickson and colleagues[35] found a greater risk gradient with density for large screen-detected 
cancers than for interval cancers. 
 
Our results are broadly consistent with those from earlier European and Northern American studies. 
Byrne and colleagues[36] collected data from women who underwent screening in the USA in the 
1970’s, and those with ≥75% breast density (as compared to those with 0% density) retained about 
a fourfold excess risk in five or more years after screening (OR: 3.56, 95% CI: 1.8-7.0, in 5-9.9 
years, and 4.47, 95% CI: 2.1-9.6, in 10-16 years). From Canada, Boyd and colleagues[32] reported 
an OR of 5.5 (95% CI: 2.7-11.2) in more than four years after screening for ≥75% vs. <10% 
density. In Sweden, Chiu and colleagues[37] showed that the cumulative incidence of breast cancer 
remained significantly increased over a 25-year period for women with dense compared to women 
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with non-dense breast patterns. An overall hazard ratio was 1.57 (95% CI: 1.23-2.01), and the 
differences between the two groups did not appear to diminish over time. Nevertheless, two other 
US studies showed some attenuation of the excess risk with time since density measurement, for 
example Thomas and colleagues[38] reported an OR of 3.4 (95% CI: 1.9-6.3) in 3-5 years, and 2.9 
(95% CI: 1.4-6.3) in ≥6 years for ≥70.3% vs. ≤26.7% density, while Yaghjyan and colleagues[39] 
reported an OR of 3.91 (95% CI: 2.22-6.88) in 5-9 years for ≥50% vs. <10% density, but a lower 
and not statistically increased OR of 1.22, 95% CI: 0.42-3.57, beyond 9 years.  
 
The fact that a single density measure in postmenopausal women retains its informational value in 
the long term may be related to a gradual stabilisation of the decline in breast density after 
menopause. McCormack and colleagues[10] estimated that breast density declines by 1.4% (95% 
CI: 1.2-1.6) per year around age 50, and by 0.7% (95% CI: 0.6-0.9) around age 57, but that the 
decline is almost 0% per year around age 65. Using cross-sectional data from 22 countries, Burton 
and colleagues[40] found that mean percent breast density declined from 27.4% at 45-49 years of 
age, to 22.5% at 50-54 and 18.7% at 55-59 years, and then stabilised around 17% from age 60 
onward. Very similar patterns were observed in multiple other studies.[7,18] This stabilisation of 
breast density after menopausal transition leads to a high degree of “tracking”, whereby women 
whose breast density ranked high on the initial mammograms still rank high on later mammograms 
despite absolute changes from the earlier to the later time point.[10] 
 
Another reason for density measurements retaining their association with breast cancer in the long 
term may be the relative inelasticity of breast cancer risk to a declining breast density. Women with 
initially high density do not experience a substantially decreased risk even in the event that their 
breast density decreases at a later age.[41,42] Consequently, sequential measurements of breast 
density improve the prediction of breast cancer risk only marginally and if so, predominantly in 
women with additional risk factors.[42] 
 
For a woman’s excess risk of breast cancer to diminish to a meaningful degree, the decrease in 
density may need to be substantially larger than the spontaneous changes brought about by aging 
and menopause, estimated at about 1% per year.[7,9,10,41] This was demonstrated in the 
International Breast Cancer Intervention Study where cancer-free high-risk women aged 30-70 
years were randomly assigned to either tamoxifen or placebo for 5 years.[22] Among those who 
used tamoxifen, 48% experienced a reduction of breast density of ≥10% points in on average 1-1.5 
years after the start of the trial. This sudden large change in density decreased the risk of cancer by 
63% (95% CI: 31-80) compared to all women on placebo.  
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CONCLUSION 
 
A single high breast density measurement identifies (postmenopausal) women who continue to have 
an excess risk of breast cancer for at least 10 years. 
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Table 1. Description of the studied women at the time of screening, by mode of cancer detection. 
 
 All cancers Screen-detected cancers Symptomatic cancers 
 Cases Controls P Cases Controls P Cases Controls P 
N 491 982  129 258  362 724  
Age, mean 
(SD) 
57.4  
(4.0) 
57.3  
(4.1) 
NR 57.9  
(4.1) 
57.8  
(4.5) 
NR 57.2  
(4.0) 
57.2  
(4.0) 
NR 
Age, 
median 
(IQR) 
56.6  
(54.3-60.5) 
56.6  
(54.1-60.6) 
NR 57.4  
(54.7-61.2) 
57.2  
(53.9-61.4) 
NR 56.3  
(54.2-60.2) 
56.5  
(54.2-60.3) 
NR 
BMI, 
median 
(IQR) 
24.7  
(22.4-27.2) 
23.9  
(21.5-26.7) 
<0.01 24.8  
(21.8-26.7) 
23.8  
(21.4-26.6) 
0.48 24.6  
(22.6-27.4) 
24.0  
(21.6-26.8) 
<0.01 
% Chinese 
 
422  
(86%) 
844  
(86%) 
NR 112  
(87%) 
224  
(87%) 
NR 310  
(86%) 
620  
(86%) 
NR 
No or 
primary 
education 
322  
(68%) 
753  
(77%) 
<0.01 92  
(71%) 
204  
(79%) 
0.09 240  
(66%) 
549  
(76%) 
<0.01 
Age at 
menarche 
≤14 years 
295  
(60%) 
514  
(52%) 
<0.01 75  
(58%) 
125  
(48%) 
0.07 220  
(61%) 
389  
(54%) 
0.02 
Premenopa
usal 
 
71  
(14%) 
109  
(11%) 
0.03 18  
(14%) 
37  
(14%) 
0.90 53  
(15%) 
72  
(10%) 
0.01 
No live 
births 
 
70  
(14%) 
95  
(10%) 
<0.01 23  
(18%) 
28  
(11%) 
0.07 47  
(13%) 
67  
(9%) 
0.06 
Ever used 
HRT 
90  
(19%) 
130  
(13%) 
<0.01 18  
(14%) 
35  
(14%) 
0.92 72  
(20%) 
95  
(13%) 
<0.01 
NR=not relevant; this was a matching variable, so inference is not applicable. 
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Table 2. Description of breast density patterns among the studied women, by mode of cancer 
detection. 
 All cancers Screen-detected cancers Symptomatic cancers 
 Cases Controls P Cases Controls P Cases Controls P 
N 491 982  129 258  362 724  
0-10% 33  
(7%) 
117  
(12%) 
 
 
 
 
<0.01 
3  
(2%) 
33  
(13%) 
 
 
 
 
<0.01 
30  
(8%) 
84  
(12%) 
 
 
 
 
<0.01 
11-25% 76  
(15%) 
282  
(29%) 
19  
(15%) 
76  
(29%) 
57  
(16%) 
206  
(28%) 
26-50% 215 
(44%) 
391  
(40%) 
58  
(45%) 
98  
(38%) 
157 
(43%) 
293  
(40%) 
51-75% 151 
(31%) 
171  
(17%) 
42  
(33%) 
45  
(17%) 
109 
(30%) 
126  
(17%) 
76-
100% 
16  
(3%) 
21  
(2%) 
7  
(5%) 
6  
(2%) 
9  
(2%) 
15  
(2%) 
Mean 
percent 
(SD) 
42  
(20) 
33  
(19) 
<0.01 46  
(20) 
33  
(20) 
<0.01 41  
(20) 
34  
(19) 
<0.01 
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Table 3. Risk of breast cancer (expressed as odds ratios) by breast density and mode of detection, 
adjusted for BMI. 
 
 All cancers Screen-detected 
cancers 
Symptomatic 
cancers 
Cases/controls 490/980 129/258 361/722 
Breast density    
0-10% 1 (ref) 1 (ref) 1 (ref) 
11-25% 1.14 (0.70-1.85) 4.32 (1.11-16.79) 0.86 (0.51-1.47) 
26-50% 2.67 (1.69-1.85) 11.53 (3.00-44.33) 1.93 (1.18-3.15) 
51-75% 4.66 (2.83-7.65) 22.24 (5.36-92.27) 3.32 (1.93-5.69) 
76-100% 5.74 (2.54-12.95) 33.74 (5.70-199.80) 3.54 (1.32-9.52) 
Per 1 percentage 
point increase 
1.03 (1.02-1.04) 1.04 (1.03-1.06) 1.03 (1.02-1.04) 
Note: Three women (1 case, 2 controls) had an unknown BMI and these trios were excluded from the 
analysis. 
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Table 4. Risk of symptomatic breast cancer (expressed as odds ratios) by breast density and time 
since screening, adjusted for BMI. 
 
 Total <1 year 1-3 years 4-6 years 7-10 years 
Cases/controls 361/722 19/38 76/152 150/299 116/233 
Breast density      
0-25% 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
26-50% 2.13  
(1.53-2.97) 
3.73  
(0.89-15.73) 
1.67  
(0.87-3.22) 
2.17  
(1.27-3.71) 
2.46  
(1.32-4.58) 
51-100% 3.70 
(2.53-5.42) 
2.87  
(0.64-12.84) 
2.22  
(1.07-4.61) 
4.09  
(2.21-7.58) 
5.35  
(2.57-11.15) 
Per 1 percentage 
point increase in 
breast density 
1.03  
(1.02-1.04) 
1.01  
(0.99-1.04) 
1.02  
(1.01-1.04) 
1.03  
(1.02-1.04) 
1.03  
(1.02-1.04) 
Note: Three women (1 case, 2 controls) had an unknown BMI and these trios were excluded from the 
analysis. 
 
 
 
 
 
